Insight Genetics Establishes Operations at CET Life Sciences Center
NASHVILLE, Tenn., Dec. 4 /PRNewswire/ -- Cumberland Emerging Technologies, Inc. (CET) (http://www.cet-fund.com/) today announced that Insight Genetics, Inc. has secured lab and office space at the CET Life Sciences Center in downtown Nashville, which is adjacent to the Union Station Hotel.
A spin-off of Nashville-based Genetic Assays, Inc., Insight Genetics was formed in January 2007 to improve the quality, safety and efficiency of disease diagnosis and treatment and make a new level of targeted drug therapy possible. The company has created a patented, highly specific genetic screening technology -- Template Exchange Extension Reaction (TEER(TM)) -- that will be a powerful tool in the emerging personalized medicine market.
Insight Genetics is exploring initial commercial applications for its TEER technology within cancer drug rescue, discovery and development, as well as early cancer detection and monitoring. The company is currently seeking partnerships that will accelerate the commercialization of TEER.
"CET is an excellent partner for early-stage and emerging bioscience companies," said Eric Dahlhauser, chief executive officer of Insight Genetics. "The support, expertise and resources CET provides companies like ours are unmatched in this region and the Life Sciences Center in downtown Nashville provides a great, central site for Insight Genetics as we grow."
The CET Life Sciences Center provides lab and office space, equipment and infrastructure support to several tenants, including the Tennessee Biotechnology Association, which has established its headquarters at the center.
"We are very pleased to welcome Insight Genetics to the Life Sciences Center," said A.J. Kazimi, chief executive officer of CET and Cumberland Pharmaceuticals Inc. "Their exciting new technology holds great promise for patient care, and we look forward to helping them grow through the start-up phase and on to commercial viability."
About CET
Cumberland Emerging Technologies, Inc. (www.cet-fund.com) is a joint initiative between Cumberland Pharmaceuticals Inc., Vanderbilt University and the Tennessee Technology Development Corporation. The mission of CET is to bring biomedical technologies and products conceived at Vanderbilt and other regional research centers to the marketplace. CET helps manage the development and commercialization process for select projects, and provides expertise on intellectual property, regulatory, manufacturing and marketing issues that are critical to successful new biomedical products. CET's Life Sciences Center, located in Nashville, Tennessee, provides laboratory space, equipment and infrastructure to early-stage life sciences companies.
CONTACT: Rebecca Kirkham of Lovell Communications Inc., +1-615-297-7766,
rebecca@lovell.com, for Cumberland Emerging Technologies, Inc.
Web site: http://www.cet-fund.com/